Cargando…
Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections
The rise in antimicrobial resistance (AMR) has complicated the management of urinary tract infections (UTIs). The objective of this study was to evaluate the antimicrobial susceptibility patterns of Escherichia coli and Klebsiella pneumoniae. Design: prospective observational study. Bacteria were cl...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687036/ https://www.ncbi.nlm.nih.gov/pubmed/36421299 http://dx.doi.org/10.3390/antibiotics11111656 |
_version_ | 1784835904050823168 |
---|---|
author | Miranda-Novales, Guadalupe Flores-Moreno, Karen López-Vidal, Yolanda Ponce de León-Rosales, Samuel |
author_facet | Miranda-Novales, Guadalupe Flores-Moreno, Karen López-Vidal, Yolanda Ponce de León-Rosales, Samuel |
author_sort | Miranda-Novales, Guadalupe |
collection | PubMed |
description | The rise in antimicrobial resistance (AMR) has complicated the management of urinary tract infections (UTIs). The objective of this study was to evaluate the antimicrobial susceptibility patterns of Escherichia coli and Klebsiella pneumoniae. Design: prospective observational study. Bacteria were classified as susceptible or resistant to ampicillin-sulbactam, amikacin, gentamicin, ciprofloxacin, norfloxacin, nitrofurantoin, trimethoprim-sulfamethoxazole (TMP/SMZ), ertapenem, meropenem, and fosfomycin. The sensitivity to fosfomycin and chloramphenicol was evaluated by the disk diffusion method. Statistical analysis: the chi-square test and Fisher’s exact test were used to compare differences between categories. A p value < 0.05 was considered statistically significant. Isolates were collected from January 2019 to November 2020 from 21 hospitals and laboratories. A total of 238 isolates were received: a total of 156 E. coli isolates and 82 K. pneumoniae isolates. The majority were community-acquired infections (64.1%). Resistance was >20% for beta-lactams, aminoglycosides, fluoroquinolones, and TMP/SMZ. For E. coli isolates, resistance was <20% for amikacin, fosfomycin, and nitrofurantoin; for K. pneumoniae, amikacin, fosfomycin, chloramphenicol, and norfloxacin. All were susceptible to carbapenems. K. pneumoniae isolates registered a higher proportion of extensively drug-resistant bacteria in comparison with E. coli (p = 0.0004). In total, multidrug-resistant bacteria represented 61% of all isolates. Isolates demonstrated high resistance to beta-lactams, fluoro-quinolones, and TMP/SMZ. |
format | Online Article Text |
id | pubmed-9687036 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96870362022-11-25 Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections Miranda-Novales, Guadalupe Flores-Moreno, Karen López-Vidal, Yolanda Ponce de León-Rosales, Samuel Antibiotics (Basel) Article The rise in antimicrobial resistance (AMR) has complicated the management of urinary tract infections (UTIs). The objective of this study was to evaluate the antimicrobial susceptibility patterns of Escherichia coli and Klebsiella pneumoniae. Design: prospective observational study. Bacteria were classified as susceptible or resistant to ampicillin-sulbactam, amikacin, gentamicin, ciprofloxacin, norfloxacin, nitrofurantoin, trimethoprim-sulfamethoxazole (TMP/SMZ), ertapenem, meropenem, and fosfomycin. The sensitivity to fosfomycin and chloramphenicol was evaluated by the disk diffusion method. Statistical analysis: the chi-square test and Fisher’s exact test were used to compare differences between categories. A p value < 0.05 was considered statistically significant. Isolates were collected from January 2019 to November 2020 from 21 hospitals and laboratories. A total of 238 isolates were received: a total of 156 E. coli isolates and 82 K. pneumoniae isolates. The majority were community-acquired infections (64.1%). Resistance was >20% for beta-lactams, aminoglycosides, fluoroquinolones, and TMP/SMZ. For E. coli isolates, resistance was <20% for amikacin, fosfomycin, and nitrofurantoin; for K. pneumoniae, amikacin, fosfomycin, chloramphenicol, and norfloxacin. All were susceptible to carbapenems. K. pneumoniae isolates registered a higher proportion of extensively drug-resistant bacteria in comparison with E. coli (p = 0.0004). In total, multidrug-resistant bacteria represented 61% of all isolates. Isolates demonstrated high resistance to beta-lactams, fluoro-quinolones, and TMP/SMZ. MDPI 2022-11-18 /pmc/articles/PMC9687036/ /pubmed/36421299 http://dx.doi.org/10.3390/antibiotics11111656 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Miranda-Novales, Guadalupe Flores-Moreno, Karen López-Vidal, Yolanda Ponce de León-Rosales, Samuel Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections |
title | Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections |
title_full | Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections |
title_fullStr | Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections |
title_full_unstemmed | Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections |
title_short | Limited Therapeutic Options in Mexico for the Treatment of Urinary Tract Infections |
title_sort | limited therapeutic options in mexico for the treatment of urinary tract infections |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9687036/ https://www.ncbi.nlm.nih.gov/pubmed/36421299 http://dx.doi.org/10.3390/antibiotics11111656 |
work_keys_str_mv | AT mirandanovalesguadalupe limitedtherapeuticoptionsinmexicoforthetreatmentofurinarytractinfections AT floresmorenokaren limitedtherapeuticoptionsinmexicoforthetreatmentofurinarytractinfections AT lopezvidalyolanda limitedtherapeuticoptionsinmexicoforthetreatmentofurinarytractinfections AT poncedeleonrosalessamuel limitedtherapeuticoptionsinmexicoforthetreatmentofurinarytractinfections AT limitedtherapeuticoptionsinmexicoforthetreatmentofurinarytractinfections |